SOD Ematologia, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
Ann Hematol. 2012 Jul;91(7):1013-22. doi: 10.1007/s00277-012-1422-5. Epub 2012 Feb 15.
Bendamustine is an alkylating agent with a nitrogen mustard group and a purine-like benzimidazole group. The aim of this study was to collect all the Italian experiences with this drug in order to evaluate the results in term of response to therapy and toxicities. We analyzed lymphoma patients treated in 24 Italian haematological centres with bendamustine alone or in combination with anti-CD20 antibody. One hundred seventy-five relapsed or refractory lymphoma patients were enrolled. The median age was 69 years (range 26-87). Seventy-nine patients were relapsed, 35 were refractory and 61 presented a progressive disease after partial response. The diagnoses were 60 indolent non-follicular lymphomas, 34 diffuse large B-cell lymphomas, 48 follicular lymphomas, 30 mantle cell lymphomas and three peripheral T-cell lymphomas. All patients were evaluable for response: 52 (29%) with complete remission, 72 (43%) with partial response with an overall response rate of 71%, and 51 non-responders. With a median observation period of 10 months (1-43), 70% of patients are alive. In summary, this retrospective study shows that treatment with bendamustine alone or in combination with rituximab is a safe and effective regimen in a subset of multi-resistant patients.
苯达莫司汀是一种烷化剂，具有氮芥基团和嘌呤样苯并咪唑基团。本研究的目的是收集所有意大利使用该药的经验，以评估其在治疗反应和毒性方面的结果。我们分析了 24 家意大利血液中心用苯达莫司汀单独或联合抗 CD20 抗体治疗的淋巴瘤患者。共纳入 175 例复发或难治性淋巴瘤患者。中位年龄为 69 岁（范围 26-87）。79 例为复发，35 例为难治，61 例为部分缓解后进展。诊断为 60 例惰性非滤泡性淋巴瘤、34 例弥漫性大 B 细胞淋巴瘤、48 例滤泡性淋巴瘤、30 例套细胞淋巴瘤和 3 例外周 T 细胞淋巴瘤。所有患者均可评估疗效：52 例完全缓解（29%），72 例部分缓解（43%），总有效率为 71%，51 例无反应。中位观察期为 10 个月（1-43），70%的患者存活。综上所述，这项回顾性研究表明，苯达莫司汀单独或联合利妥昔单抗治疗是一组多耐药患者安全有效的方案。
